


Better AWR Outcomes. Reinforced by Data.



GORE® BIO-A® Tissue Reinforcement offers proven low complication rates in high risk AWR patients¹ vs. BARD® DAVOL PHASIX Mesh.

Proven **LOW** Complication Rates



1. Literature search and summary. (data on file 2018; W. L. Gore & Associates, Inc.; Flagstaff, AZ.)

2. LaPere DB, Lundgren MP, Rosato EL, et al. Single institution Phasix mesh outcomes in a population of primarily complicated/recurrent hernias. Presented at the 11th Annual Academic Surgical Congress; February 2-4, 2016; Jacksonville, FL. Abstract 69.16.



10 YEARS EFFECTIVE CLINICAL USE

Complex and high-risk AWR cases
Hiatal / Paraesophageal hernia repair
Demonstrated economic value

- **MORE** than 150 publications
- **LOW** recurrence rates in hiatal hernias
- **LOW** recurrence rates in complex ventral hernias
- **OVER 1700** patients in the clinical literature
- **TARGETED** absorption period avoids the risk for long-term mesh-related complications
- **LOWER** cost alternative to other non-permanent products



W. L. GORE & ASSOCIATES, INC.

Flagstaff, AZ 86004

+65.67332882 (Asia Pacific) 800.437.8181 (United States)
00800.6334.4673 (Europe) 928.779.2771 (United States)

goremedical.com

Refer to *Instructions for Use* for a complete description of all warnings, precautions, and contraindications. ®, ©

Products listed may not be available in all markets.

BARD® DAVOL and PHASIX are trademarks of Davol, Inc. a subsidiary of C.R. Bard, Inc.

GORE®, BIO-A®, and designs are trademarks of W. L. Gore & Associates. © 2018 W. L. Gore & Associates, Inc. AX1202-EN1 AUGUST 2018